Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.
Third time was the charm for Alkermes' experimental antidepressant ALKS 5461.
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.